Posted inNews PrEP Prevention Research Twice-yearly lenacapavir 89% more effective than Truvada Posted by By Tom Hayes-Isaacs 2024-09-24 New data from the PURPOSE 2 study shows that twice-yearly lenacapavir is 89% more effective…
Posted inConferences News Research Treatment HIV viral rebounds following CRISPR gene therapy Posted by By Tom Hayes-Isaacs 2024-08-06 EBT-101, a gene-editing therapy utilising CRISPR technology, showed promising safety and tolerability in an initial…
Posted inHealthcare Medicines News Parenting PrEP Prevention Research Cabotegravir PrEP injection is safe during pregnancy Posted by By Tom Hayes-Isaacs 2024-07-30 The safety and tolerability of long-acting injectable cabotegravir (CAB-LA) as HIV pre-exposure prophylaxis (PrEP) for…